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SUMMARY
Glucagon is secreted from pancreatic a cells, and
hypersecretion (hyperglucagonemia) contributes to
diabetic hyperglycemia. Molecular heterogeneity
in hyperglucagonemia is poorly investigated. By
screening human plasma using high-resolution-pro-
teomics, we identified several glucagon variants,
among which proglucagon 1-61 (PG 1-61) appears
to be the most abundant form. PG 1-61 is secreted
in subjects with obesity, both before and after gastric
bypass surgery, with protein and fat as the main
drivers for secretion before surgery, but glucose af-
ter. Studies in hepatocytes and in b cells demon-
strated that PG 1-61 dose-dependently increases
levels of cAMP, through the glucagon receptor, and
increases insulin secretion and protein levels of en-
zymes regulating glycogenolysis and gluconeogen-
esis. In rats, PG 1-61 increases blood glucose and
plasma insulin and decreases plasma levels of amino
acids in vivo. We conclude that glucagon variants,
such as PG 1-61, may contribute to glucose regula-
tion by stimulating hepatic glucose production and
insulin secretion.
INTRODUCTION
Glucagon is a peptide hormone secreted from pancreatic
a cells in response to hypoglycemia and hyperaminoacidemia
(Gromada et al., 2007). Hypersecretion of glucagon (hypergluca-
gonemia) is an important element of the pathophysiology of dia-
betes and contributes to its pathogenesis (Unger and Cherring-
ton, 2012).
The glucagon gene (GCG), which encodes the precursor
molecule of glucagon, proglucagon (PG), is expressed in
pancreatic a cells, in enteroendocrine L cells and in the brain
stem (Vrang and Larsen, 2010). The processing of PG is strictly
regulated by the differential expression of the two prohormone
convertases, 2 (PC2) and 1/3 (PC1), which, in a cells, gives rise
to glucagon (because of PC2 activity), while in the L cells, which
express PC1, a number of ‘‘glucagon-like’’ hormones, including
the incretin hormone glucagon-like peptide-1 (GLP-1) are
formed (Figure 1A). Heterogeneity of the products of PG (in
particular, PC2-dependent processing) has previously been re-
ported in patients with glucagon-producing tumors (Holst,
1983) (glucagonoma) and in uremic pigs (Baldissera and Holst,
1986). However, the extent to which molecular heterogeneity is
normally seen and whether it is involved in diabetes and/or other
metabolically related diseases are unknown (Unger and Cher-
rington, 2012).
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In thepresent study,we investigated themolecular heterogene-
ity of PG products in conditions known to be associated with hy-
perglucagonemia, such as post gastric bypass, type 2 diabetes,
and renal failure. An N-terminally elongated glucagon molecule,
PG 1-61, was identified using a mass spectrometry-based prote-
omic platform. Furthermore, using an array of in vitro and in vivo
studies, we demonstrate that PG 1-61 possesses gluco-regula-
toryeffects throughactivationof theglucagon receptor expressed
in pancreatic b cells and hepatocytes.
RESULTS
PG 1-61 Identified in Human Plasma by Mass
Spectrometry, Immunoassays, and Size-Exclusion
Chromatography
We identified an N-terminally elongated glucagonmolecule using
a validated and unbiased mass-spectrometry-based platform
(Figures 1B and 1C), corresponding to the amino acid sequence
of PG 1-61 (RSLQDTEEKSRSFSASQADPLSDPDQMNEDKRHS
Figure 1. PG 1-61, a Glucagon Variant, Identified in Human Plasma by Mass Spectrometry
(A) Overview of the processing of proglucagon (1-160). In the pancreas, proglucagon is processed by prohormone convertase 2 (PC2), resulting in the formation of
glicentin-related pancreatic polypeptide (GRPP), glucagon, and the major proglucagon fragment. In the intestine, the actions of prohormone convertase 1/3
(PC1/3) lead to the formation of glicentin, glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2). Below, potential (denoted as X and Y)
N-terminally elongated and C-terminally truncated forms of glucagon are depicted.
(B) A mass-spectrometry-based platform for identification of low-abundant peptides such as glucagon. In short, blood is taken from a subject, and the plasma is
subjected to ultra-pressure liquid chromatography (UPLC), and the peptides are sprayed into an Orbitrap-based mass spectrometer, using an electrospray
technique (ESI). The identified spectra are deconvoluted into amino acid sequences using the MaxQuant software package.
(C) Separate plasma pools, obtained from subjects with kidney failure (n = 8) and from healthy subjects (n = 8), were subjected to the platform shown in (B), and the
corresponding amino acid intensities are depicted as red (kidney failure) and green (healthy subjects). Synthesized PG 1-61 (positive control) is depicted in blue.
(D) By comparing plasma levels of immunoreactive total glucagon (i.e., PG 1-61 + PG 33-61 [glucagon]), using a C-terminal assay (blue), to plasma levels of PG
1-61 (black) and glucagon 33-61 (red) using two sandwich ELISAs, we were able to verify immunoreactive PG 1-61 in plasma in response to an oral glucose load
(E) in the same kidney failure individuals used in our mass-spectrometry-based platform (C).
(F) Size-exclusion chromatography identified two major immunoreactive glucagon-like moieties using the C-terminal assay (blue): one identified having similar
coefficient of distribution (Kd) as recombinant PG 1-61 (Kd = 0.22) (only immunoreactive peak identified using the PG 1-61 assay, black curve) and one similar to
pancreatic glucagon (33-61) (Kd = 0.8).
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QGTFTSDYSKYLDSRRAQDFVQWLMNT), in plasma from pa-
tients with hyperglucagonemia due to kidney failure (end-stage
renal disease [ESRD]) but not in plasma from healthy controls.
Furthermore, we identified several other N-terminally elongated
glucagon variants, but their abundancies were much less
(10-fold) compared to those of PG 1-61 (Figure S1).
The structure of the N-terminally elongated glucagon variant
was consistent with its reactions toward two sandwich ELISAs:
lack of reactivity in an assay specific for fully processed glucagon
and full reactivity inanassaydesigned for reactionwithPG1-61,as
well as in a validated C-terminal-specific glucagon radioimmuno-
assay (Figure 1D). Secretory profiles of glucagon-like immunore-
activity assessed by a C-terminal assay were almost superimpos-
able to a profile calculated as the sum of fully processed glucagon
and PG1-61 concentrations (Figure 1E) (AUC0-180min for the C-ter-
minal assay = 4,021± 195min3 pM, compared to AUC0-180min for
the twosandwichELISAs: 4,102± 219min3pM,p=0.74). Finally,
size-exclusion chromatography of pooled plasma, from the same
kidney failure patientsasdescribedabove,withconcomitantmea-
surements with a C-terminal glucagon assay and a PG 1-61 spe-
Figure 2. PG 1-61 Responses in Subjects
with a Variety of Clinical Conditions Charac-
terized with Hyperglucagonemia
(A) Plasma levels of PG 1-61 during an oral glucose
tolerance test (0-min time point was analyzed and
is shown) in subjects with kidney failure (end-stage
renal disease) before, 3 months, and 12 months
after renal transplantation.
(B) PG 1-61 responses during a meal stimulation
test (black) and an oral glucose tolerance test
(OGTT) (red) in subjects with type 2 diabetes (T2D).
(C) PG 1-61 responses during an oral glucose load
(red), fat ingestion (blue), or protein ingestion
(black) in obese subjects.
(D) PG 1-61 (red) and glucagon (black) responses
during an L-arginine test in healthy subjects
(circles) or in gastric-bypass-operated subjects
(squares) (Roux-en-Y gastric bypass).
(E) PG 1-61 responses during an oral glucose
tolerance test (red), fat ingestion (blue), or protein
ingestion (black) in gastric-bypass-operated sub-
jects (Roux-en-Y gastric bypass).
(F) PG 1-61 responses during an oral glucose
tolerance test in fully pancreatectomized subjects
(PX). n = 8–12.
cific assay, identified a peak (Kd = 0.28)
corresponding to that of exogenous PG
1-61 (Figure 1F), thereby independently
verifying the results obtained using the
mass-spectrometry-based platform.
PG 1-61 Is Secreted in Several
Clinical Conditions Associated with
Hyperglucagonemia
Thirteen out of 14 patients with renal
dysfunction had measurable plasma
levels of PG 1-61, which dropped signifi-
cantly (p < 0.001) 3 months after renal
transplantation (in parallel with normalization of the kidney func-
tion), and remained stable at a 12-month follow-up (Figure 2A).
There were no differences in plasma levels of PG 1-61 in kidney
failure patients with diabetes compared to those with normal
glucose tolerance (7 in total). To investigate whether immuno-
reactive PG 1-61 is only found in subjects with insufficient
renal plasma clearance (end-stage renal disease), we analyzed
plasma from subjects with other pathologies associated with hy-
perglucagonemia, namely, type 2 diabetes and morbid obesity.
No detectable PG 1-61was found in plasma from patients with
type 2 diabetes during an oral glucose tolerance test (OGTT)
(concentrations remained around the detection limit of the sand-
wich ELISA1 pM) (Figure 2B), whereasmeasurable levels were
found during a meal stimulation test (nAUC0-240min, OGTT 182 ±
90 min 3 pM, compared to meal AUC0–240min. meal stimulation
1,430 ± 284 min 3 pM, respectively, p < 0.01). In obese
subjects, protein and fat ingestion increased plasma levels of
PG 1-61 (Figure 2C). In contrast, glucose ingestion was not asso-
ciatedwith any rise in PG1-61 levels, and, if anything, therewas a
trend for levels to be reduced. Extracts of gut biopsies (mucosa)
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from obese subjects did not contain immunoreactive PG 1-61
(<1 pmol/g) but had high levels of other peptides derived from in-
testinal processing of proglucagon (GLP-1, 58 ± 12 pmol/g; gli-
centin, 102 ± 23 pmol/g; oxyntomodulin, 32 ± 6 pmol/g), all three
derived from the proglucagon-expressing L cells. Furthermore,
extracts from three human healthy pancreases showed detect-
able levels of PG 1-61 (above limits of detection), although
compared to glucagon this was rather low (PG 1-61: 2 pmol/g,
glucagon 29 pmol/mg). Collectively, suggesting that PG 1-61 in
some conditions may be derived from pancreatic a cells and
co-secreted with pancreatic glucagon.
In both Roux-en-Y gastric bypass (RYGB)-operated and BMI-
matched obese individuals, i.v. administration of L-arginine (an
a cell secretagogue) robustly stimulated glucagon secretion (Fig-
ure 2D). PG1-61 levelswere also increased in the obese controls,
albeit to amuch lower extent than glucagon, but remained unde-
tectable in the gastric bypass subjects (Figure 2D). Furthermore,
glucose, but not fat and protein, elicited a secretory PG 1-61
response in gastric bypass individuals (Figure 2E). In pancreatec-
Figure 3. PG 1-61 Activates GCGR and Reg-
ulates Blood Glucose by Stimulating Insulin
Secretion from Cultured b Cells and Iso-
lated Pancreases
(A and B) PG 1-61 activated the human glucagon
receptor (hGCGR) (A) but not the human glucagon-
like peptide 1 receptor (hGLP-1R) (B) with same
efficacy butwith lower potency compared tonative
glucagon in transiently transfected COS-7 cells
expressing hGCGR (A) and hGLP-1R (B).
(C) PG 1-61 dose-dependently stimulated levels of
cAMP in INS1cells.Positivecontrol (PC), consisting
of Bombesin, Forskolin, and IBMX, is shown.
(D) PG 1-61 (1 nM) stimulated the secretion of
insulin in INS1 cells; thus, this could be signifi-
cantly reduced by small interfering RNA of the
glucagon receptor (red), compared to small
interfering RNA control (black). PBS was used as
negative control, L-arginine was used as a posi-
tive control, and glucagon was used as compar-
ator to the effects of PG 1-61.
(E) Perfusions of isolated rat pancreases (n = 6)
with PG 1-61 (1 nM), glucagon (1 nM), and
L-arginine as positive control. PG 1-61 significantly
(***p < 0.001) increased insulin secretion. n = 6–8.
tomized patients, where the surgery re-
sults in similar anatomical rearrangement
of the gastrointestinal tract as after
Roux-en-Y gastric bypass surgery, an
oral glucose load led tomodest increases
in PG 1-61 plasma levels (Figure 2F).
PG 1-61 Activates the Glucagon
Receptor, Stimulates Insulin
Secretion in b Cells, and Increases
Blood Glucose in Rats
In transiently transfected COS-7 cells,
synthetic PG 1-61 (synthesized accord-
ing to the sequence identified in humans)
activated the human glucagon receptor (hGCGR) as a full
agonist with a 100-fold decreased potency compared to native
glucagon (LogEC50, PG 1-61 = 8.0 ± 0.22 compared to
LogEC50, glucagon =10.0 ± 0.17) (Figure 3A). In contrast, it acted
with very low potency on cells expressing hGLP-1R and only
reached 38% of Emax of GLP-1 at a concentration of 1 mM,
whereas glucagon acted as a partial agonist with 100-fold
lower potency and an Emax of 78% compared to native GLP-1
(LogEC50, PG 1-61 < 6, compared to LogEC50, glucagon = 8.2 ±
0.08 and LogEC50, GLP-1 = 10.2 ± 0.11) (Figure 3B).
PG 1-61 dose-dependently increased accumulation of cAMP
in cultured rat b cells (INS1) (Figure 3C) and significantly stimu-
lated insulin release compared to PBS administration alone
(Figure 3D, p < 0.001). The effect was comparable to that of
native glucagon. In INS1 cells with small interfering RNA
(siRNA)-induced knockdown of the rat glucagon receptor
(rGCGR) knockdown estimated to 70% by qPCR, data not
shown), PG 1-61-induced insulin secretion was significantly
blunted compared to small interfering RNA mock-treated cells
Cell Reports 21, 1452–1460, November 7, 2017 1455
(Figure 3D, p < 0.01). Perfusion of isolated rat pancreases with
PG 1-61 (1 nM) resulted in significant increases in insulin secre-
tion compared to baseline (tAUC1-61: 3,534 ± 321 min 3 pM
versus tAUCbaseline: 2,073 ± 521min3 pM, p < 0.001) (Figure 3E).
i.v. administrationofPG1-61 (1nM) in rats resulted ina rapidand
robust increase in blood glucose compared to mannitol-treated
rats (iAUC0–20min: 41 ± 9 min 3 mM versus 11 ± 10 min 3 mM,
p < 0.001) (Figure 4A). Plasma insulin increased transiently in
response to both PG 1-61 and glucagon administration, but not
mannitol (Figure 4B), and the summedmolarity of amino acids (to-
tal plasma levels of amino acids) decreased (Figure 4C). PG 1-61
inhibited the secretion of pancreatic glucagon measured using a
highly specific sandwich ELISA (Figure 4D) (which does not react
with PG 1-61, unlike ‘‘traditional’’ (C-terminally directed) glucagon
assays). Analysis of plasma using the two specific sandwich
ELISAs for PG 1-61 and pancreatic glucagon, respectively,
confirmed their specificity (i.e., no measureable PG1-61 in rats
receiving exogenous glucagon and vice versa [Figures 4E and
4F]). Moreover, the observation that immunoreactive glucagon
Figure 4. PG 1-61 Regulates Blood Glucose
in Rats by Stimulating Insulin Secretion
Intravenous injection with mannitol (1 g/kg, gray),
PG 1-61 (1 pmol, red), or glucagon (1 pmol, black)
in rats. Mannitol was used as a control for volume
and osmolarity. Plasma samples were obtained
subsequently during a 20-min period.
(A and B) Both blood glucose (A) and plasma in-
sulin levels (B) increased significantly after the in-
jection of PG 1-61 and glucagon, respectively.
(C) Plasma amino acids decreased significantly
after the injection of PG 1-61 and glucagon.
(D) Plasma glucagon levels decreased signifi-
cantly after injection of PG 1-61 (red) but not
mannitol (gray).
(E and F) Plasma levels of PG 1-61 (E) in PG 1-61,
glucagon, andmannitol-treated ratsareshown,and
plasma levels of glucagon (F) in PG 1-61, glucagon,
and mannitol-treated rats are shown. n = 4–8.
was not detected in the PG 1-61-treated
rats indicates that PG 1-61 is not cleaved
in the plasma to form glucagon. Adminis-
tration of PG 1-61 to diabetic animal
models did, however, not seem to inhibit
the secretion of glucagon (Figure S2).
PG 1-61 Increases cAMP Levels in
Primary Human Hepatocytes and
Increases the Expression of
Enzymes Related to
Gluconeogenesis in the HEP1 Cell
Line in a Glucagon Receptor-
Dependent Manner
PG 1-61 dose-dependently increased
intracellular levels of cAMP in primary
humanhepatocytes (HMCS10) (Figure5A)
and in cultured human hepatocytes
(HepG2) (Figure 5B). Small interfering
RNA knockdown of hGCGR (knockdown estimated to 75%
by qPCR, Figure S3) attenuated both PG 1-61 and glucagon-
stimulated increases in cAMP compared to small interfering
RNA-treated controls in cultured hepatocytes (Figure 5B). 30-
min incubationwith PG1-61 significantly increased protein levels
of the enzymes protein kinase A (PKA), glucose-6-phosphatase
(G6P), phosphorylase kinase (PKC-1), glycogen phosphorylase
(GP), andphosphoenolpyruvate carboxykinase (PECK), essential
for the regulation of gluconeogenesis and glycogenolysis (Fig-
ure 5C). In small interfering RNA-treated cells, the protein levels
of these enzymes tended to be lower. Incubation for 3 hr with
PG 1-61 showed more pronounced effects on the protein levels
of protein kinase A, G6P, PKC-1, GP, and PECK (Figure 5D). Cor-
responding western blots are shown in Figures S3, S4, and S5.
DISCUSSION
Here, we unequivocally identified a glucagon variant (PG 1-61)
in humans, using a mass-spectrometry-based platform for
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low-abundant plasma peptides (Wewer Albrechtsen et al., 2016),
and subsequently characterized its potential biological functions
in vitro, ex vivo, and in vivo. Collectively, our data suggest that
circulating PG 1-61 may contribute to the dysregulation of
glucose homeostasis in clinical conditions including renal
dysfunction, obesity, type 2 diabetes, and after Roux-en-Y
gastric bypass, whereas its circulating levels in healthy lean con-
trols did not exceed our analytical detection limit.
First, we demonstrated that PG 1-61 activates the hGCGR, but
not the hGLP-1R, with similar efficacy as native glucagon but
with lower potency. PG 1-61, like glucagon, increased cAMP
and insulin secretion in cultured b cells mediated through
GCGR signaling, as evidenced by the reduced effect seen after
small interfering RNA induced knockdown of GCGR. A similar ef-
fect of PG 1-61 on insulin secretion was also observed in isolated
rat pancreases, and, when it was given in vivo (intravenously,
aimed at reaching similar concentrations to those used in the
ex vivo experiments), blood glucose increased and plasma levels
of amino acids decreased. The liver is the primary target for
glucagon, and, accordingly, PG 1-61 also had hepatic effects.
In primary hepatocytes expressing GCGR, PG 1-61 increased
levels of cAMP, and this may be associated with relatively small
changes in protein levels of enzymes related to the processes of
glycogenolysis and gluconeogenesis. However, the latter need
to be confirmed in future studies.
Our findings and previous observations (Holst, 1983, Challis
et al., 2015, Baldissera and Holst, 1986, Rouille´ et al., 1994,
Friis-Hansen et al., 2001) suggest that a residual plasticity in pro-
glucagon-producing cells may exist. A single study (Holst, 1983),
comparing the gel filtration profiles of plasma from healthy con-
trols to patients with glucagon-producing tumors, reported
glucagon-like immunoreactivity with an estimated molecular
size of 8,000 Da; however, that variant may actually represent
another proglucagon-derived peptide, glicentin (PG 1–—69,
8,100 Da), as it contains the entire sequence of glucagon and
reacts with antisera directed toward the glucagon sequence.
Using an unbiased mass-spectrometry-based platform, we
identified a peptide having the same amino acid sequence as
the first 61 amino acids of the proglucagon molecule. Mass-
spectrometry technologies can be superior to immune-based
assays as they have an absolute specificity (Aebersold and
Mann, 2016), but they can be very laborious. We therefore
(together with Mercodia) developed an ELISA specific for PG
1-61 in humans, the accuracy of which was validated using the
same mass-spectrometry platform as well as gel filtration chro-
matography. This sandwich ELISA allowed us to obtain secre-
tory profiles of PG 1-61 in subjects with hyperglucagonemia of
differing etiologies.
In a previous study in subjects with end-stage renal disease,
we found that immunoreactive glucagon concentrations differed
Figure 5. PG 1-61 Stimulates cAMPProduc-
tion in Primary and Cultured Human Hepa-
tocytes and Increases Protein Content of
Enzymes Related to Gluconeogenesis and
Glycogenolysis
(A) PG 1-61 stimulated cAMP production dose-
dependently (10–1,000 pM) in primary human he-
patocytes. As negative control (NC), we used PBS,
and, as positive control (GCG), we used 100 pM
glucagon.
(B) PG 1-61 stimulated cAMP production dose-
dependently (10–1,000 pM) in cultured human
hepatocytes (HepG2). Small interfering RNAmock
and small interfering RNA glucagon receptor
(siRNA GCGR)-mediated knockdown are shown.
As negative control (NC), we used PBS, and, as
positive control (GCG), we used 100 pM glucagon.
(C) PG1-61 (red, 1,000 pM) increased protein
levels (30 min of incubation) of glucose-6-phos-
phatase (G6P), phosphorylase kinase (PKC-1),
glycogen phosphorylase (GP), and phosphoenol-
pyruvate carboxykinase (PECK). Administration of
glucagon (1,000 pM) is shown in black.
(D) PG1-61 (red) increased protein levels (3-hr
incubation) of protein kinase A (PKA), glucose-
6-phosphatase (G6P), phosphorylase kinase
(PKC-1), glycogen phosphorylase (GP), and
phosphoenolpyruvate carboxykinase (PECK). In
small interfering RNA-treated cells, the protein
levels of these enzymes were not significantly
different from PBS-treated cells (white). Corre-
sponding original western blots are shown in Fig-
ure S4, and uncropped blots are shown in Figures
S5 and S6. **p < 0.01, ***p < 0.001 tested using
one-way ANOVA corrected for multiple testing
(Sidak-Holm). n = 3–6.
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according to the immunoassay employed (higher using a
C-terminally directed glucagon assay compared to a sandwich
ELISA combiningN-andC-terminal antibodies) (WewerAlbrecht-
sen et al., 2014), indicating that the apparent hyperglucagonemia
was not due to elevated levels of fully processed glucagon.
Analyzing plasma samples from these subjects in the current
study established PG 1-61 as the major circulating glucagon
variant, with levels increasing in response to an oral glucose
load. However, after kidney transplantation, levels of immunore-
active PG 1-61 were dramatically reduced, suggesting that the
increased levels observed before transplantation likely reflect
decreased renal clearance of this component rather than adap-
tive changes in proglucagon producing cells leading to increased
secretion. On the other hand, given the complete absence of PG
1-61 in the plasma from healthy subjects, it cannot be fully
excluded that the presence of this component in the subjects
with renal insufficiency might be associated specifically with
some aspect of the pathology of their disease. In addition, as
glucagon may be affected by freeze-thaw cycles (Wewer Al-
brechtsen et al., 2015) the same could be true for PG 1-61, and,
as such, wemay therefore underestimate plasma concentrations
of PG1-61. PG1-61 could also have adirect effect on the kidneys
and thereby contribute to regulate gluconeogenesis; however,
further studies will be needed to explore these possibilities.
PG 1-61 was not detected in plasma from subjects with type 2
diabetes during oral glucose administration, but a meal chal-
lenge did lead to an increase in plasma levels. Moreover, in
morbidly obese subjects and in gastric-bypass-operated indi-
viduals, plasma levels of PG 1-61 increased in response to oral
administration of macronutrients, but, intriguingly, the magni-
tude of the responses to the different stimuli varied between
the two groups of subjects. In obese subjects, both protein
and fat led to increases in immunoreactive PG 1-61, whereas
glucose was without effect (as was also seen in subjects with
type 2 diabetes). In contrast, in the gastric-bypass-operated
individuals, glucose seems to constitute the major driver for
PG 1-61 secretion, with only minor effects of protein and fat.
These observations raise questions, not only about the mecha-
nisms leading to PG 1-61 secretion, but also about its origin: in
the gut or the pancreas? In support of gut-derived PG 1-61,
the anatomical rearrangements associated with total pancrea-
tectomy also lead to glucose-induced PG 1-61 secretion. As
such, it seems that the molecular heterogeneity of hypergluca-
gonemia may be derived either from the pancreatic a cells in
subjects with obesity and or type 2 diabetes, or from enteroen-
docrine L cells scattered along the small intestine in patients
with rearrangement of such anatomical compartments. The re-
sidual plasticity, activated uponmetabolic or anatomical alterna-
tions, in both a cells and L cells may therefore reflect a potential
path to understand and to target dysmetabolic conditions.
Plasmaconcentrations of PG1-61were relatively low (picomo-
lar range), which may be related to the instability of themolecule,
as we previously shown for glucagon (Wewer Albrechtsen et al.,
2015), and, since it also had lower potency on the glucagon re-
ceptor compared to the native peptide, onemayquestion its rele-
vance to dysregulated glucose metabolism in diabetes. That
said, PG 1-61 did have glucose regulatory capabilities in human
hepatocytes and did significantly increase blood glucose levels
in the in vivo rat studies, supporting a role for PG 1-61 in glucose
metabolism at least under these circumstances. PG 1-61may be
subject to further cleavage, thereby potentially generating in-
creases in plasma glucagon concentration. However, i.v. injec-
tion in ratswas not associatedwith increases in plasma glucagon
levels—rather glucagon tended to decrease, which might reflect
a negative feedbackmechanism involving the interactionwith the
glucagon receptor on pancreatic a cells. However, in diabetic an-
imal models, PG 1-61 did not inhibit secretion of glucagon, sug-
gesting that such a negative feedback circuit may be blunted in
diabetic animals, as a consequence of their hyperglycemia.
In conclusion, we have demonstrated that molecular hetero-
geneity of glucagon exists, with PG 1-61 being amajor additional
component. Hyperglucagonemia may therefore, not only reflect
hypersecretion of fully processed glucagon, but also of PG 1-61.
Moreover, given that PG 1-61 can increase hepatic glucose
production and insulin secretion, at least in in vitro and animal
studies, it may influence glucose homeostasis in a variety of
metabolically related conditions, which are associated with
hyperglucagonemia.
EXPERIMENTAL PROCEDURES
Approvals
The clinical studies were conducted according to the latest revision of the Hel-
sinki Declaration, approved by the Scientific-Ethical Committee of the Capital
Region of Denmark (H-C-2009-007, H-1-2012-123, H-1-2013-063) and/or the
regional ethics committee (KF-01279825) and registered by the Danish Data
Protection Agency (2016-41-4892, 2007-58-0015), and at ClinicalTrials.gov
(NCT01327378, NCT02372526, NCT02006459, NCT02161666). All partici-
pants gave informed written consent. Animal studies were conducted with
permission from the Danish Animal Experiments Inspectorate (2013-15-
2934-00833) and approved by the local ethical committee (P-15-335, P15-
369, P-14-213, and P 17-266).
Study Design
Reserve plasma samples, collected during an oral glucose tolerance test, from
individuals with end-stage renal disease and matched, healthy controls were
obtained from a comparative, observational study as described previously
(Idorn et al., 2013). These samples were used for mass-spectrometry and
size-exclusion chromatography and ELISA measurements. Reserve plasma
samples from individuals with end-stage renal disease; fasting plasma and
during an oral glucose test from 14 individuals, including nine with normal
glucose tolerance, were obtained before and after kidney transplantation as
part of a prospective, observational, national multicenter study including 54
of 81 (67%) patients, mostly Caucasians, with scheduled living donor kidney
transplantation in the period between January 2006 and March 2008, as
described previously (Hornum et al., 2010).
Reserve plasma samples from Roux-en-Y gastric bypass-operated sub-
jects, BMI-matched obese individuals (Dirksen et al., 2016; Z.C. Jensen
et al., 2016, Diabetes, conference) and subjects with type 2 diabetes (Baranov
et al., 2016, Jørgensen et al., 2012) were obtained from previous studies. Par-
ticipants underwent oral glucose tolerance test or meal stimulation with isoca-
loric, isovolemic meals of either glucose, fat, or protein (Z.C. Jensen et al.,
2016, Diabetes, conference); in addition, we performed L-arginine stimulation
tests (Dirksen et al., 2016). Finally, plasma from a previously published study
in pancreatectomized patients during an oral glucose tolerance test was
analyzed (Lund et al., 2016). Gut biopsies from obese individuals were from
a previously published study (Rhee et al., 2015).
Animal Studies
Male Wistar rats (250 g, from Taconic Ejby) were housed two per cage under
standard conditions for at least 1 week before experiments. Experiments were
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carried out on non-fasted rats immediately before their nocturnal feeding
period (1,700 hr). Rats were divided into three weight-matched treatment
groups (glucagon: 265 ± 2 g; PG 1-61: 264 ± 3 g; and D-mannitol: 264 ± 3 g,
n = 6/group) and received an intravenous (i.v.) bolus of test substance
dissolved in 0.9% NaCl so that the injection volume was 1.5 mL/300 g body
weight (w/v, D-mannitol: 20.2%); rats from the same cage received different
treatments.
For further details, see Supplemental Experimental Procedures.
Isolated Perfused Rat Pancreas
See Supplemental Experimental Procedures.
Cell-Culture Experiments
INS-1E cells were kindly provided by Professor Jens Højriis Nielsen (University
of Copenhagen, Denmark). Cells were grown in DMEM (cat. no. 31966-021,
GIBCO) containing 5,000 U/mL Pen-Strep (cat. no. 15140-122, GIBCO) and
10% fetal bovine serum (FBS) (cat. no. Sv3016003, Thermo Scientific) before
being seeded in 24-well plates (Nunc, Thermo Scientific) at a cell density of
43 104 per well. Primary human hepatocytes were obtained using CellStream
Isolation Technology (cat. no. HMCS10, lot. no. HUE50-F, Thermo Scientific).
See Supplemental Experimental Procedures.
Receptor Studies
See Supplemental Experimental Procedures.
qPCR and Small Interfering RNAs
See Supplemental Experimental Procedures.
Western Blot Analysis
See Supplemental Experimental Procedures.
Peptides and Antibodies
See Supplemental Experimental Procedures.
Biochemical Measurements
Glucagon levels were measured using a previously validated sandwich ELISA
(Mercodia: cat. no. 10-1281/1271 [Wewer Albrechtsen et al., 2014]) employing
an N-terminal anti-glucagon antibody as capture antibody and a C-terminal-
specific anti-glucagon antibody as detection antibody. Levels of N-terminally
elongated glucagon (PG 1-61) were measured using a sandwich ELISA
(Mercodia, presently not commercially available), employing an N-terminal
antibody specific for the N-terminal region of the proglucagonmolecule (amino
acid sequence RSLQDTEE) and the same C-terminal specific anti-glucagon
antibody as detection antibody (see above). Insulin levels were measured us-
ing a sandwich ELISA from Mercodia (cat. no. 10-1250). cAMP was measured
according to manufacturer’s protocol as described above.
Gel Filtration of Human Plasma
Further details are described in Supplemental Experimental Procedures and
elsewhere (Challis et al., 2015).
Mass-Spectrometry-Based Detection of Glucagon
Plasma samples were analyzed using a mass-spectrometry-driven platform
(Wewer Albrechtsen et al., 2016), with antibody-independent prefractionation
steps providing unbiased estimation of the various glucagon forms. See Sup-
plemental Experimental Procedures.
Data and Materials Availability
The accession number for the mass spectrometry proteomics data reported in
this paper is ProteomeXchange Consortium via the PRIDE partner repository:
PXD005677.
Calculations and Statistics
One-way ANOVA corrected by a post hoc analysis (Sidak) for multiple testing
was used for testing differences between more than two groups. Unpaired
two-sided t test was used to assess differences between two groups.
p < 0.05 was considered significant. Calculations were made using GraphPad
Prism version 6.04 for Windows, GraphPad Software, https://www.graphpad.
com and STAT14 (SE). For illustrations, the Adobe CC software suite
was used. Data are shown as mean ± SD. See Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2017.10.034.
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